Table 3

Treatment frequency and its number of eyes

Overall2010–20122011–20132012–20142013–20152014–20162015–2017P value for ANOVAP value for trend test
Anti-VEGFn=1234
(60.2%)		n=80
(58.8%)		n=107
(37.5%)		n=201
(55.1%)		n=324
(58.8%)		n=343
(73.3%)		n=179
(73.4%)		<0.001<0.001
Number of times3.8±3.32.5±1.81.8±1.52.9±2.73.5±3.04.7±3.75.5±3.6<0.001<0.001
Bevacizumabn=635
(31.0%)		n=80
(58.8%)		n=103
(36.1%)		n=180
(49.3%)		n=224
(40.7%)		n=37
(7.9%)		n=11
(4.5%)		<0.001<0.001
Number of times2.2±2.02.5±1.71.6±0.92.4±2.32.4±2.21.9±1.31.3±0.50.0030.969
Ranibizumabn=578
(28.2%)		n=2
(1.5%)		n=4
(1.4%)		n=44
(12.1%)		n=152
(27.6%)		n=284
(60.7%)		n=92
(37.7%)		<0.001<0.001
Number of times3.3±2.81.01.0±0.02.1±1.62.9±2.33.4±3.14.2±2.8<0.001<0.001
Afliberceptn=336
(16.4%)		n=1
(0.7%)		n=4
(1.4%)		n=14
(3.8%)		n=69
(12.5%)		n=139
(29.7%)		n=109
(44.7%)		<0.001<0.001
Number of times4.1±3.02.05.0±4.13.5±2.82.4±1.94.0±2.95.4±3.3<0.001<0.001
Corticosteroidn=1077
(52.6%)		n=66
(48.5%)		n=145
(50.9%)		n=195
(53.4%)		n=345
(62.6%)		n=220
(47.0%)		n=106
(43.4%)		<0.0010.137
Number of times2.0±1.31.9±1.22.0±1.32.1±1.32.0±1.42.2±1.41.7±1.10.0970.517
Intravitreal TAn=162
(7.9%)		n=8
(5.9%)		n=4
(1.4%)		n=42
(11.5%)		n=66
(12.0%)		n=28
(6.0%)		n=14
(5.7%)		<0.0010.466
Number of times1.7±1.11.4±0.72.0±0.81.5±0.71.6±1.22.4±1.51.7±1.10.0140.034
Subtenon TAn=966
(47.1%)		n=62
(45.6%)		n=144
(50.5%)		n=167
(45.8%)		n=288
(52.3%)		n=205
(43.8%)		n=100
(41.0%)		0.0200.094
Number of times2.0±1.31.9±1.22.0±1.22.0±1.42.1±1.32.0±1.21.6±1.00.0220.117
Macular PCn=746
(36.4%)		n=40
(29.4%)		n=122
(42.8%)		n=141
(38.6%)		n=236
(42.8%)		n=154
(32.9%)		n=53
(21.7%)		<0.001<0.001
Number of times1.9±1.41.7±1.11.9±1.42.0±1.41.8±1.32.0±1.61.3±0.60.0100.339
Vitrectomyn=597
(29.1%)		n=64
(47.1%)		n=125
(43.9%)		n=115
(31.5%)		n=148
(26.9%)		n=76
(16.2%)		n=69
(28.3%)		<0.001<0.001
Number of times1.1±0.31.1±0.31.1±0.31.1±0.21.0±0.21.0±0.21.1±0.20.5580.221

  • Data about number of times were presented as mean value ±SD.

  • ANOVA, analysis of variance; PC, photocoagulation; TA, triamcinolone acetonide; VEGF, vascular endothelial growth factor.